Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
Rational of study : 3,4-diaminopyridine is suspected to improved the fatigue associated in
patient's multiple sclerosis.
In order to confirm this hypothesis, a randomized, controlled versus placebo, double blinded
study is performed.